Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 288 participants.

Also called NCT03281538

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 288 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03281538
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03281538. Allocation not applicable; no masking; primary purpose treatment. Start 2017-08-14 (actual); primary completion 2020-02-11 (actual). Results posted on 2021-10-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Condition
Uremic Pruritus
Intervention (Drug)
CR845
Lead sponsor
Cara Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03281538
Content hash
27bda13ab0aeea89a873464b872cd8cb1cf0e72569fe204a826ca822b81a9b98